Eir Ventures

Plus: Early-stage financings for InduPro, Syntis and Moleculent; J.P. Morgan closes its life sciences vehicle; and a new fund for spinal injury

Plus: Pain, hearing loss company Hoba raises €23M and more from Novartis, Cogent and Zafrens

Arch-incubated newco launched Monday with $72.5M and three platforms to tackle mitochondrial diseases

Plus CureVac hiring Novartis’ Mendila, adding antigen discovery platform via Frame takeout, and updates from Aldeyra, Astellas, PineTree and more

Plus AbbVie, Venatorx meet in Phase III and updates from MorphoSys, RefleXion, TG Therapeutics, Xeris and more

Plus: FDA delivers RWE guidance, ACT for ALS clears House and more

IO Biotech parlayed early clinical data into a €127 million ($154.8 million) series B financing led by HBM Healthcare Investments, which will support a Phase II trial of its leading cancer

Ironwood to downsize after Phase III GERD failureIronwood Pharmaceuticals Inc. (NASDAQ:IRWD) said it plans to discontinue development of IW-3718 after the therapy missed the primary endpoint in a

FDA moving quickly on Biogen’s aducanumab Biogen Inc. (NASDAQ:BIIB) added $1.4 billion in market cap Monday, as its shares rose $8.73 (3.2%) to $282.04, after FDA said it will hold an

The new firm believes Scandinavia offers high-quality science in a market with few dedicated VCs